$2.50
0.35[16.28%]
At close: Apr 22
$2.50
0[0.00%]
After Hours: 7:58PM EDT
CytoMed Therapeutics
(NASDAQ:GDTC)CytoMed Therapeutics Stock (NASDAQ:GDTC), Analyst Ratings, Price Targets, Predictions
CytoMed Therapeutics Ltd has a consensus price target of $5, established from looking at the 2 latest analyst ratings. The last 2 analyst ratings were released from Benchmark and Benchmark on December 4, 2023 and July 21, 2023. With an average price target of $5 between Benchmark and Benchmark, there's an implied 100.00% upside for CytoMed Therapeutics Ltd from these 2 analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for CytoMed Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/04/2023 | GDTC | Buy Now | CytoMed Therapeutics | $2.50 | 100% | Benchmark | Bruce Jackson | → $5 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 07/21/2023 | GDTC | Buy Now | CytoMed Therapeutics | $2.50 | 100% | Benchmark | Bruce Jackson | → $5 | Initiates | → Speculative Buy | Get Alert |
FAQ
What is the target price for CytoMed Therapeutics (GDTC)?
The latest price target for CytoMed Therapeutics (NASDAQ: GDTC) was reported by Benchmark on December 4, 2023. The analyst firm set a price target for $5.00 expecting GDTC to rise to within 12 months (a possible 100.00% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CytoMed Therapeutics (GDTC)?
The latest analyst rating for CytoMed Therapeutics (NASDAQ: GDTC) was provided by Benchmark, and CytoMed Therapeutics reiterated their speculative buy rating.
When was the last upgrade for CytoMed Therapeutics (GDTC)?
There is no last upgrade for CytoMed Therapeutics.
When was the last downgrade for CytoMed Therapeutics (GDTC)?
There is no last downgrade for CytoMed Therapeutics.
When is the next analyst rating going to be posted or updated for CytoMed Therapeutics (GDTC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytoMed Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytoMed Therapeutics was filed on December 4, 2023 so you should expect the next rating to be made available sometime around December 4, 2024.
Is the Analyst Rating CytoMed Therapeutics (GDTC) correct?
While ratings are subjective and will change, the latest CytoMed Therapeutics (GDTC) rating was a reiterated with a price target of $0.00 to $5.00. The current price CytoMed Therapeutics (GDTC) is trading at is $2.50, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.